All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

1,268

Reset

1,268 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • COM701Phase 21 trial

    Compugen Ltd · Ovarian Cancer, Ovarian Cancer Recurrent

  • CORT125236NenocorilantPhase 21 trial

    Corcept Therapeutics · Neoplasms

  • CP-383Phase 21 trial

    Tasca Therapeutics · Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC )

  • CPT-11Phase 21 trial

    Zhejiang Doer Biologics Co., Ltd. · Gastrointestinal Cancer

  • CR-001Phase 21 trial

    Crescent Biopharma, Inc. · Locally Advanced / Metastatic Solid Tumors

  • CR-002Phase 21 trial

    Crescent Biopharma, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)

  • CR6086vorbipiprantPhase 21 trial

    Rottapharm Biotech · Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer

  • CRG-150Phase 21 trial

    CoRegen, Inc. · HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer

  • CRN09682Phase 21 trial

    Crinetics Pharmaceuticals Inc. · SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm

  • CS2009Phase 21 trial

    CStone Pharmaceuticals · Advanced Solid Tumors

  • CS5006Phase 21 trial

    CStone Pharmaceuticals · Advanced Solid Tumors

  • CT041Phase 21 trial

    CARsgen Therapeutics Co., Ltd. · Gastric Cancer, Pancreatic Cancer

  • CT3001Phase 21 trial

    Crossignal Therapeutics, Inc. · Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

  • CTS3497Phase 21 trial

    CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma

  • CTX-471Phase 21 trial

    Compass Therapeutics · Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

  • DA-4505Phase 21 trial

    Dong-A ST Co., Ltd. · Locally Advanced or Metastatic Solid Tumors

  • DanvatirsenAZD9150Phase 21 trial

    AstraZeneca · Non-Small Cell Lung Cancer

  • DAT-2645Phase 21 trial

    Danatlas Pharmaceuticals Co., Ltd · Advanced or Metastatic Ovarian Cancer

  • DB-1310Phase 21 trial

    DualityBio Inc. · Advanced Solid Tumor

  • DB-1324Phase 21 trial

    DualityBio Inc. · Gastrointestinal Cancer

  • DB-1419Phase 21 trial

    DualityBio Inc. · Solid Tumor, Adult

  • DC05F01Phase 21 trial

    Heronova Pharmaceuticals · Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer

  • DCC-3009Phase 21 trial

    Deciphera Pharmaceuticals, LLC · Gastrointestinal Stromal Tumor (GIST)

  • Debio 4228Phase 21 trial

    Debiopharm International SA · Prostate Cancer

  • Decoy20Phase 21 trial

    Indaptus Therapeutics, Inc · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)

  • DES-1357Phase 21 trial

    D. E. Shaw Research, LLC · Metastatic Colorectal Cancer (CRC)

  • DF1001Phase 21 trial

    Dragonfly Therapeutics · Solid Tumor, Adult

  • DF9001Phase 21 trial

    Dragonfly Therapeutics · Solid Tumor, Adult

  • DJI136Phase 21 trial

    Novartis · Extensive-stage Small Cell Lung Cancer (ES-SCLC)

  • DKN-01LY2812176Phase 21 trial

    Leap Therapeutics, Inc. · Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer

  • DM002Phase 21 trial

    Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

  • DM005Phase 21 trial

    Doma Biopharmaceutical(Suzhou)Co., Ltd. · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma

  • DocetetaxelPhase 21 trial

    Merck & Co. · Carcinoma, Non-Small-Cell Lung

  • DR30206Phase 21 trial

    Zhejiang Doer Biologics Co., Ltd. · Gastrointestinal Cancer

  • DS-1103aPhase 21 trial

    Daiichi Sankyo · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

  • DT-7012Phase 21 trial

    Domain Therapeutics Australia Pty Ltd · Advanced Solid Tumors

  • DXC006Phase 21 trial

    Hangzhou DAC Biotechnology Co., Ltd. · Small Cell Lung Cancer

  • DYP688Phase 21 trial

    Novartis · Metastatic Uveal Melanoma

  • E7090Phase 21 trial

    Eisai · Cholangiocarcinoma

  • E7386Phase 21 trial

    Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular

  • E7389-LFPhase 21 trial

    Eisai · Solid Neoplasms

  • EB-701CA9-NKPhase 21 trial

    Beijing Biotech · Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  • ECI830Phase 21 trial

    Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer

  • EF-009Phase 21 trial

    Everfront Biotech Co., Ltd. · Pancreatic Cancer

  • EfineptakinNT-I7, rhIL-7-hyFcPhase 21 trial

    NeoImmuneTech · Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer

  • EG-70Phase 21 trial

    enGene, Inc. · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer

  • EGL-001Phase 21 trial

    Egle Therapeutics · Solid Tumor, Adult

  • EIK1004-001IMP1707-001Phase 21 trial

    Eikon Therapeutics · Advanced Solid Tumors

  • EIK1005Phase 21 trial

    Eikon Therapeutics · Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer

NewerPage 17 of 26Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.